# Analytical Pharmacology Core

> **NIH NIH P30** · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · 2020 · $118,680

## Abstract

Analytical Pharmacology Core Facility Shared Resource
ABSTRACT
The Analytical Pharmacology Core Facility (APCF) encourages and facilitates collaborative research between
basic scientists and clinicians by providing comprehensive analytical and consultative services in a GLP-capable
environment. The APCF assists with the design and implementation of pharmacokinetic, pharmacodynamic, and
biomarker correlative studies for clinical and preclinical investigations of small molecules and biologic agents
(e.g., antibodies, antisense oligonucleotides, vaccines, and cellular therapeutics).
Primary services provided are: 1) quantitative assay development and sample analysis (LC-MS/MS, ICP-MS,
GC/MS, HPLC, Luminex, ELISA, qPCR) of drugs, biomarkers, and related compounds; and 2) study design and
expert analysis of pharmacokinetic and biomarker data.
All major analytical equipment is consolidated into a contiguous suite of rooms in the Shapiro building. The most
heavily utilized major equipment within the core are the LC-MS/MS instruments and the FLEXMAP 3D multiplex
immunoassay platform. Mass spectrometry instrumentation includes a Micromass Quattro Ultima triple quad, a
Waters Quattro Premier XE triple quad, an AB Sciex QTRAP 5500, an Agilent 6410, and a recently acquired
Waters Xevo-TQXS. All systems provide state-of-the-art selectivity and sensitivity for detecting and quantifying
analytes in complex biological matrices and are interfaced with HPLC front-end components. Additional key core
equipment include an Agilent 8800 inductively-coupled plasma triple quadrupole mass spectrometer (ICP-MS)
for determination of metals and metal-containing compounds and four complete HPLC systems. For analysis of
biological agents, the Core has a FLEXMAP 3D Bioplex instrument for multiplex immunoassays, a Bio-Rad
QX200 Droplet Digital PCR for absolute quantitation of gene expression, a FLUOstar OPTIMA multi-label plate
reader for a wide range of high-throughput ELISA applications, and a Guava PCA-96 analytical cell analyzer.
The core is directed by Dr. Timothy Synold, a Professor in the Department of Cancer Biology, with oversight by
an interdisciplinary faculty Advisory Committee. Dr. Synold actively participates in most of the early drug
development efforts within the Divisions of Hematology and Medical Oncology, which is reflected in the heavy
usage by members of the DCT and HM Programs. User feedback is provided annually through user surveys.
Since the last competitive renewal, the APCF contributed to 44 publications by CC members. Over the past five
years, the APCF was used by a total of 74 unique investigators, including 56 CC members from all five Programs.
Of the 56 CC members, 46 (82%) had peer-reviewed funding. During this period, 147 unique analytical methods
were developed or re-initiated and 24,502 samples were analyzed. In addition, 4,632 clinical specimens were
processed and 75 separate cancer clinical trials were supported by the core.

## Key facts

- **NIH application ID:** 9849205
- **Project number:** 5P30CA033572-37
- **Recipient organization:** BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
- **Principal Investigator:** TIMOTHY W SYNOLD
- **Activity code:** P30 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $118,680
- **Award type:** 5
- **Project period:** — → —

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/9849205

## Citation

> US National Institutes of Health, RePORTER application 9849205, Analytical Pharmacology Core (5P30CA033572-37). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/9849205. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*